Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Köksal, Hakan, Dillard, Pierre, Josefsson, Sarah E., Maggadottir, Solrun Melkorka, Pollmann, Sylvie, Fåne, Anne, Blaker, Yngvild Nuvin, Beiske, Klaus, Huse, Kanutte, Kolstad, Arne, Holte, Harald, Kvalheim, Gunnar, Smeland, Erlend B., Myklebust, June H., Inderberg, Else Marit, Wälchli, Sébastien
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482360/
https://ncbi.nlm.nih.gov/pubmed/30979721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029678
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados